NP 339
Alternative Names: Novamycin®; NP-339; NP525Latest Information Update: 28 Oct 2024
At a glance
- Originator NovaBiotics
- Class Antifungals; Peptides; Peptidomimetics
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Oropharyngeal candidiasis
- No development reported Invasive bronchopulmonary aspergillosis
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Oropharyngeal candidiasis in United Kingdom (PO)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Invasive-bronchopulmonary-aspergillosis in United Kingdom (Inhalation, Aerosol)
- 01 Jun 2021 Preclinical trials in Oropharyngeal candidiasis in United Kingdom (IV)